Predictive nature of IgM anti-alpha-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis

M.S. Freedman, C. Metzig, L. Kappos, C.H. Polman, G. Edan, H.P. Hartung, D. H. Miller, X. Montalban, J. Yarden, L. Spector, E. Fire, N. Dotan, S. Schwenke, V. Lanius, R. Sandbrink, C. Pohl

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)966-973
JournalMultiple Sclerosis
Issue number7
Publication statusPublished - 2012

Cite this